Table 2.
Top 10 overlapping pairs of Medications with Actionable Pharmacogenomic Biomarkers
| MAPB1 | Biomarker1 | MAPB2 | Biomarker2 | Number of enrollees | Percent of enrollees |
|---|---|---|---|---|---|
| Age 0–17 (N 439,828) | |||||
| methylphenidate | CYP2D6 | sertraline | CYP2C19, CYP2D6 | 1,130 | 0.26 |
| amphetamine | CYP2D6 | sertraline | CYP2C19, CYP2D6 | 569 | 0.13 |
| escitalopram | CYP2C19, CYP2D6, SLCC6A4 | methylphenidate | CYP2D6 | 469 | 0.11 |
| aripiprazole | CYP2D6 | sertraline | CYP2C19, CYP2D6 | 411 | 0.09 |
| aripiprazole | CYP2D6 | methylphenidate | CYP2D6 | 394 | 0.09 |
| methylphenidate | CYP2D6 | risperidone | CYP2D6 | 297 | 0.07 |
| aripiprazole | CYP2D6 | escitalopram | CYP2C19, CYP2D6, SLCC6A4 | 274 | 0.06 |
| atomoxetine | CYP2D6 | methylphenidate | CYP2D6 | 265 | 0.06 |
| amphetamine | CYP2D6 | escitalopram | CYP2C19, CYP2D6, SLCC6A4 | 256 | 0.06 |
| amphetamine | CYP2D6 | methylphenidate | CYP2D6 | 241 | 0.05 |
| Age 18–64 (N 1,657,143) | |||||
| metoprolol | CYP2D6 | rosuvastatin | ABCG2, SLCO1B1 | 7,045 | 0.43 |
| metoprolol | CYP2D6 | pantoprazole | CYP2C19 | 5,666 | 0.34 |
| clopidogrel | CYP2C19 | metoprolol | CYP2D6 | 5,252 | 0.32 |
| metoprolol | CYP2D6 | simvastatin | SLCO1B1 | 5,142 | 0.31 |
| metoprolol | CYP2D6 | omeprazole | CYP2C19 | 5,104 | 0.31 |
| meloxicam | CYP2C9 | omeprazole | CYP2C19 | 3,624 | 0.22 |
| omeprazole | CYP2C19 | simvastatin | SLCO1B1 | 3,534 | 0.21 |
| pantoprazole | CYP2C19 | rosuvastatin | ABCG2, SLCO1B1 | 3,515 | 0.21 |
| meloxicam | CYP2C9 | metoprolol | CYP2D6 | 3,495 | 0.21 |
| omeprazole | CYP2C19 | rosuvastatin | ABCG2, SLCO1B1 | 3,391 | 0.20 |
Abbreviations. MAPB= Medications with an Actionable Pharmacogenomic Biomarker, N= total number enrolled in the healthcare plans with continuous pharmacy coverage.
Patients are included in the number of enrollees if they were dispensed the same pair of drugs for a time period of at least 30 consecutive days.